Pharmaceutical composition for treating fibrosis
AssigneesLTT Bio-Pharma Co., Ltd., Musashino University
InventorsTohru Mizushima, Ken-ichiro Tanaka
Life of this patent
Estimating the term…
Abstract
To provide a novel therapeutic agent for fibrosis that induces selective cell death of lung fibroblasts and suppresses lung fibrosis without injuring alvocar epithelial cells. A pharmaceutical composition for treating fibrosis, the pharmaceutical composition comprising a compound of formula (I) or formula (II): wherein in formula (I), R1 represents a C1-4 alkyl group optionally substituted with a halogen atom, and l represents an integer of 3 to 6; and in formula (II), n represents an integer of 8 to 12, or a pharmaceutically acceptable salt thereof or a solvate of the compound or the salt thereof.
Claims6
A method for treating fibrosis, the method comprising administering to a subject in need thereof an effective amount of a compound of the following formula (I):
- wherein R1 represents a C1-4 alkyl group optionally substituted with a halogen atom, and l represents an integer of 3 to 6,
- or a pharmaceutically acceptable salt thereof or a solvate of the compound or the salt thereof,
- wherein the fibrosis is idiopathic pulmonary fibrosis.
Dependencies are inferred from the claim text.